FirstWord

Third-quarter revenue jumped 29% to $1.3 billion as the biotech swung to profit.

The collaboration, focused on developing RNA editing candidates for cardiometabolic diseases, was on the rocks after being paused in Nov. last year.

J&J's EGFR/MET inhibitor achieved a 42% overall response rate in the Phase Ib/II OrigAMI-4 trial involving patients with previously treated head and neck squamous cell carcinoma (HNSCC).

The company confirms nine cases since the gene therapy's first approval in 2019, including two that have shown evidence of vector DNA integration.

Merck determined that the mid, 7-mg dose of efinopegdutide had the most favourable benefit-risk profile in patients with metabolic dysfunction-associated steatohepatitis (MASH).

FirstWord spoke with UCSF oncologist Sima Porten about detailed Phase III VOLGA data for AstraZeneca's Imfinzi as perioperative therapy for muscle-invasive bladder cancer, and how it might impact other drugs like Merck's Keytruda as well as Pfizer and Astellas' Padcev.

BETHESDA, Md., Nov. 6, 2026 /PRNewswire/ -- Precision Biologics, Inc. CEO Philip M. Arlen, MD announces presentation of new data describing in-vivo efficacy of its novel tumor-specific antibody-drug-c...

In vivo-engineered TRAC-CAR T cells demonstrate complete leukemia tumor clearance in mice, including following tumor rechallenge without additional dosing Modular platform enables dual-antigen targeti...

Remarkable 9.1-month median progression-free survival and 28% confirmed objective response rate in heavily pretreated melanoma patients receiving imneskibart triplet regimen with nivolumab, including ...

Colorectal cancer: in a human liver-metastasis organoid model resistant to botensilimab and balstilimab alone, the addition of agenT-797 supported immune reprogramming and tumor-cell killing, reinforc...